What are the ultrasound features of non‑alcoholic steatohepatitis (NASH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ultrasound Features of NASH

Ultrasound cannot distinguish NASH from simple steatosis (NAFL), as it only detects hepatic fat content and cannot visualize the inflammation and hepatocyte ballooning that define NASH. 1

What Ultrasound Can Show

Hepatic Steatosis Features (Not Specific to NASH)

Conventional ultrasound detects fatty infiltration through increased liver echogenicity, graded as 2:

  • Mild steatosis: Mild diffuse increase in liver echogenicity with clear visualization of diaphragm and intrahepatic vessel walls
  • Moderate steatosis: Mild diffuse increase in liver echogenicity with obscuration of diaphragm and intrahepatic vessel walls
  • Severe steatosis: Marked increase in liver echogenicity with non-visualization of diaphragm and intrahepatic vessel walls

Performance limitations: Ultrasound has 84.8% sensitivity and 93.6% specificity for moderate-to-severe steatosis (>30% fat content), but sensitivity drops to 53.3-65% for mild steatosis. Specificity further deteriorates when inflammation or fibrosis is present—the exact features that define NASH. 2

Advanced Ultrasound Techniques

Quantitative Hepatorenal Index

The hepatorenal index (comparing liver to kidney echogenicity) shows excellent correlation with fat fraction (AUC 99.2-99.6%) and is independent of BMI, inflammation, or fibrosis 2. However, this still only quantifies steatosis, not NASH.

Controlled Attenuation Parameter (CAP)

CAP via transient elastography measures ultrasound attenuation to quantify fat deposition 1:

  • Korean cutoffs: 250 dB/m (mild), 299 dB/m (moderate), 327 dB/m (severe steatosis)
  • Critical limitation: CAP cannot distinguish NASH from NAFL

Shear Wave Elastography (SWE)

SWE measures liver stiffness to assess fibrosis, not NASH itself. One study found vessel blurring on ultrasound was the only independent predictor of NASH (sensitivity 93%, specificity lower) 3, but the diagnostic performance was poor (AUC 0.649) for differentiating steatosis from NASH.

The Clinical Reality

The fundamental problem: NASH requires histologic evidence of hepatocyte ballooning and lobular inflammation in addition to steatosis 1. Ultrasound—regardless of technique—cannot visualize cellular injury or inflammation.

When to Suspect NASH Beyond Ultrasound Findings

Look for 2:

  • AST:ALT ratio <1 (metabolic disease pattern)
  • Metabolic syndrome components (obesity, diabetes, dyslipidemia)
  • Persistent aminotransferase elevation despite steatosis on imaging

What You Actually Need for NASH Diagnosis

Liver biopsy remains the gold standard 1. Consider biopsy when:

  • Advanced fibrosis is suspected (use elastography + fibrosis scores like FIB-4 or NFS first)
  • Need to exclude other liver diseases
  • Patient has high-risk features (diabetes, metabolic syndrome, obesity)

Bottom line: Use ultrasound to screen for and grade steatosis in at-risk populations (diabetes, metabolic syndrome, elevated liver enzymes) 1. When ultrasound shows steatosis, combine with elastography for fibrosis assessment and clinical/laboratory parameters to stratify NASH risk. Reserve biopsy for high-risk patients where the diagnosis will change management.

References

Guideline

acr appropriateness criteria® abnormal liver function tests.

Journal of the American College of Radiology, 2023

Research

Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.